Short Interest in RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) Decreases By 73.1%

RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) saw a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 22,000 shares, a drop of 73.1% from the March 31st total of 81,700 shares. Based on an average trading volume of 7,859,600 shares, the days-to-cover ratio is presently 0.0 days.

RespireRx Pharmaceuticals Stock Performance

OTCMKTS:RSPI traded up $0.00 on Friday, reaching $0.00. 3,727,442 shares of the stock traded hands, compared to its average volume of 12,020,596. The company has a market capitalization of $697,212.00, a PE ratio of -0.04 and a beta of 0.49. RespireRx Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.02.

About RespireRx Pharmaceuticals

RespireRx Pharmaceuticals Inc engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors.